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Adelaide, Australia
Objectives Using 2 sequential studies in HOPE (Heart Outcomes Prevention Evaluation) study–type patients, the aims of this
study were: 1) to test the hypothesis that ramipril improves platelet nitric oxide (NO) responsiveness: and 2) to
explore biochemical and physiological effects of ramipril in a cohort selected on the basis of platelet NO resistance.
Background Ramipril prevents cardiovascular events, but the bases for these effects remain uncertain. NO resistance at both
the platelet and vascular levels is present in a substantial proportion of patients with diabetes or ischemic heart
disease and is an independent risk factor for cardiovascular events.
Methods Study 1 was a double-blind, randomized comparison of ramipril (10 mg) with placebo in a cohort of patients
(n  119) with ischemic heart disease or diabetes plus additional coronary risk factor(s), in which effects on
platelet responsiveness to NO were compared. Study 2 was a subsequent short-term evaluation of the effects of
ramipril in a cohort of subjects (n  19) with impaired platelet NO responsiveness in whom additional mechanis-
tic data were sought.
Results In study 1, ramipril therapy increased platelet responsiveness to NO relative to the extent of aggregation (p 
0.001), but this effect occurred primarily in patients with severely impaired baseline NO responsiveness (n 
41). In study 2, ramipril also improved platelet NO responsiveness (p  0.01), and this improvement was corre-
lated directly with increased NO-stimulated platelet generation of cyclic guanosine monophosphate (p  0.02)
but not with changes in plasma thrombospondin-1 levels.
Conclusions Ramipril ameliorates platelet NO resistance in HOPE study–type patients, with associated increases in soluble
guanylate cyclase responsiveness to NO. This effect is likely to contribute to treatment benefit and define pa-
tients in whom ramipril therapy is particularly effective. (J Am Coll Cardiol 2012;60:887–94) © 2012 by the
American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.01.066The HOPE (Heart Outcomes Prevention Evaluation) study
with ramipril (1) and the EUROPA (European Trial on
Reduction of Cardiac Events With Perindopril in Stable
Coronary Artery Disease) study with perindopril (2) proved
that angiotensin-converting enzyme (ACE) inhibitors re-
duce the risk for cardiovascular events in aging, high-risk
populations. Furthermore, rates of myocardial infarction,
stroke, cardiac arrest, heart failure, and complications relat-
ing to diabetes were also decreased. However, the mecha-
nism(s) underlying these beneficial effects have never been
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2012, accepted January 23, 2012.delineated and have been the subject of considerable spec-
ulation (3–8). Although ACE inhibitors reduce the inci-
dence of fatal and nonfatal atherothrombotic-related events
in patients with either chronic heart failure (9,10) or
evidence of heart failure after acute myocardial infarction
(11,12), evaluation of potential interactions between ACE
inhibitors and platelets has been limited. Enalapril has been
reported not to affect aggregation (13) and lisinopril not to
change soluble P-selectin levels (14).
See page 895
In our previous investigation of perindopril effects in
patients with heart failure (15), there was also no significant
change in platelet aggregability. However, platelet responses
to nitric oxide (NO) donor (both inhibition of aggregation and
increase in intraplatelet cyclic guanosinemonophosphate [cGMP]
concentration), which were impaired at baseline, were normalized
with perindopril therapy, thus manifesting an improvement
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Ramipril Reverses Platelet NO Resistance September 4, 2012:887–94in NO/cGMP signaling. Indeed,
platelet hyporesponsiveness to NO,
as a part of a general phenomenon of
“tissue NO resistance” (16), occurs
commonly in patients with symp-
tomatic ischemic heart disease (17–
19) and in those with diabetes (20)
and represents an independent
marker of increased cardiovascular
risk (21). The NO/cGMP signaling
pathway is a physiologically impor-
tant modulator of both vasomotor
tone and platelet function. NO re-
sistance is defined as an impaired
physiological response to endoge-
nous and exogenous NO and may
predispose to increased risk for isch-
emic or thrombotic events (16).
We therefore have conducted 2
sequential investigations in HOPE
study–type patients: the first to test
the hypothesis that ramipril improves platelet NO responsiveness
in such patients across an entire study cohort and the second to
explore the cellular mechanism underlying this effect in a pre-
selected subset of patients exhibitingNO resistance. The results of
both studies suggest that restoration of NO responsiveness by
ramipril therapy contributed to its beneficial clinical effects in the
HOPE study.
Methods
Study 1: randomized comparison: SUBJECTS. In study 1, a
total of 119 patients who were at high cardiovascular risk
were enrolled. Inclusion criteria were similar to those of the
HOPE study (1). Eligible patients were men and women
age 50 years (vs. 55 years in the HOPE study) who had
histories of coronary artery disease, stroke, peripheral vas-
cular disease, and/or diabetes plus 1 other risk factor
(hypertension, elevated total cholesterol level, low high-
density lipoprotein cholesterol level, cigarette smoking, or
documented microalbuminuria). Patients were excluded if
they had symptomatic heart failure; were taking ACE
inhibitors, angiotensin receptor antagonists, or adenosine
5=-diphosphate (ADP) receptor antagonists; had uncon-
trolled hypertension; had clinically overt renal insufficiency;
or had had a myocardial infarction or stroke within 4 weeks
of study entry. Platelet hyporesponsiveness to ADP (4 
response) was also an exclusion criterion (see the following
discussion).
STUDY DESIGN. The study consisted of a randomized,
lacebo-controlled, blinded evaluation of the effects of
amipril on platelet responsiveness to sodium nitroprusside
SNP). Additionally, the effects of ramipril on endothelial
unction were assessed, using plasma levels of asymmetric
imethylarginine (ADMA), a marker of endothelial dys-
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
ADMA  asymmetric
dimethylarginine
ADP  adenosine
5=-diphosphate
AIx  augmentation index
cGMP  cyclic guanosine
monophosphate
MDA  malondialdehyde
NO  nitric oxide
PRP  platelet-rich plasma
sGC  soluble guanylate
cyclase
SNP  sodium
nitroprusside
TSP  thrombospondinunction (22), together with the augmentation index (AIx),marker of apparent arterial stiffness (23,24). Changes in
lasma concentrations of malondialdehyde (MDA) were
etermined as indexes of oxidative stress (25).
Potentially eligible patients (n  202) attended a screen-
ng session at which blood samples were collected for the
easurement of platelet aggregation. Patients who had
ore than 4  of ADP-induced aggregation (n  119; see
Platelet Aggregation Studies”) were randomized to receive
amipril or matched placebo (provided by Aventis Pharma-
euticals, Bridgewater, New Jersey) on the basis of a
andomization program. Ramipril was initiated at 5 mg/day.
fter 1 week of therapy, all patients returned, and ramipril
ose was up-titrated to 10 mg/day unless contraindicated
e.g., because of significant cough or symptomatic hypoten-
ion). Blood samples were collected from all patients at
aseline and after 4 and 12 weeks of therapy; AIx was also
easured at each visit.
BLOOD SAMPLING. Blood samples were drawn by veni-
puncture from an antecubital vein. Blood was collected into
plastic tubes containing 1:10 volume of acid citrate (2 parts
0.1 mol/l citric acid to 3 parts 0.1 mol/l trisodium citrate)
and used for whole-blood platelet aggregation studies.
PLATELET AGGREGATION STUDIES. All aggregation studies
ere performed using a dual-channel impedance aggregom-
ter (model 560, Chrono-Log, Havertown, Pennsylvania) as
reviously described (17). Aggregation was induced with
DP (final concentration 1 or 2.5 mol/l), and responses
were recorded for electrical impedance () using a computer
interface system (Aggrolink, Chrono-Log). Responses to
the NO donor SNP rather than nitroglycerin were used as
indexes of platelet responsiveness to NO to avert any
potential effect of nitrate tolerance on assessment of platelet
function (26). SNP (final concentration 10 mol/l) was
added to samples 1 min before ADP. Inhibition of aggre-
gation by SNP was evaluated as a percent of maximal
aggregation in the absence of SNP. To minimize inaccura-
cies in the calculation of the inhibitory effect of SNP, at least
4  of ADP response was required.
APPLANATION TONOMETRY. We used applanation tonom-
etry to evaluate the effects of ramipril on arterial stiffness.
Pulsed-wave analysis was used to determine AIx (AtCor
Medical, Sydney, Australia) as previously described (23,24).
Briefly, a micromanometer probe (SPT-301B, Millar In-
struments, Houston, Texas) was used to obtain recordings
of the peripheral pressure waveforms by flattening, but not
occluding, the radial artery of the dominant arm. Data were
collected directly into the SphygmoCor system (AtCor
Medical), and after 20 sequential waveforms had been
acquired, an average peripheral waveform was generated.
The waveform was then scaled from brachial artery blood
pressure. The corresponding central (ascending aortic)
waveform was derived from the radial artery waveform using
a validated transfer function; from this augmentation, a
value of AIx was then derived and corrected for heart rate.
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September 4, 2012:887–94 Ramipril Reverses Platelet NO ResistanceBIOCHEMICAL MARKERS. Plasma concentrations of the en-
dogenous NO synthase inhibitor ADMA were measured as
previously described (22) using high-performance liquid
chromatography. MDA was determined using a modified
thiobarbituric acid method (25).
Study 2: mechanistic considerations: Study 2, performed
subsequent to the evaluation of study 1 results, was designed
to evaluate the relationship between the effects of ramipril
treatment on responsiveness of platelet soluble guanylate
cyclase (sGC). In view of the heterogeneity of results in
study 1, we selected a more NO resistant cohort by
excluding patients with baseline SNP response 50%. A
total of 19 patients with similar inclusion and exclusion
criteria as described previously were enrolled for this study.
Ramipril was initiated at 5 mg/day for 1 week, after which
the dose was up-titrated to 10 mg/day. Blood samples were
collected from patients at baseline and after 2 weeks of
therapy. Platelet aggregation studies were performed as
described previously.
CGMP STUDIES. For cGMP studies, blood was centrifuged
at 250 g for 10 min at room temperature to obtain
platelet-rich plasma (PRP). Platelet-poor plasma was pre-
pared by further centrifugation of the remaining blood at
2,500 g for 20 min. Platelet counts were performed on the
STKS Coulter Counter (Coulter Electronics Inc., Hialeah,
Florida) and the PRP was adjusted with platelet-poor
plasma to a constant count of 250,000/l.
PRP (0.5 ml) was pre-incubated at 37°C with SNP (10
mol/l) for 1 min to assess the effect of NO donor on
intraplatelet cGMP content. Intraplatelet generation of
cGMP in the presence of the phosphodiesterase inhibitor
3-isobutyl-1-methylxanthine (0.5 mmol/l, 5 min pre-
incubation with PRP before SNP addition) was determined
as a measure of NO responsiveness of platelet sGC. Intra-
platelet cGMP content was assayed as described previously
(27). Briefly, after incubation, PRP was filtered through
GF/C Glass Microfibre Filters (Whatman, Maidstone,
United Kingdom) for harvesting the platelets. Filters with
absorbed platelets were rinsed with physiological saline and
placed into 0.5 ml of 4 mmol/l ethylenediaminetetraacetic
acid for further extraction of cGMP in a boiling water bath
for 5 min. After centrifugation of samples at 3,000 g for 10
in, cGMP concentration in supernatant was estimated
sing cGMP radioimmunoassay kits [125I] (Biomedical
Technologies Inc., Stoughton, Massachusetts).
THROMBOSPONDIN (TSP)-1. Plasma concentrations of
SP-1, a platelet-derived endogenous inhibitor of intracel-
ular NO signaling and particularly of sGC (28), were
etermined before and after ramipril therapy. For determi-
ation of TSP-1 levels, blood was centrifuged at 1,800 g for
5 min at 4°C, and the supernatant was collected. The
upernatant was recentrifuged at 10,000 g for 10 min,
ollected, and stored at 70°C. Determination of TSP-1
evels was then performed per the Quantikine Human sSP-1 enzyme-linked immunosorbent assay kit (R&D
ystems, Minneapolis, Minnesota).
Both studies were approved by the Ethics of Research
ommittee of the Queen Elizabeth Hospital, and written
nformed consent was obtained before study entry.
tatistical analysis: All data were analyzed via intention to
reat. Patients were categorized according to entry platelet NO
esponsiveness. Study 1 was powered to detect 0.75-SD
ariability in platelet SNP responses between treatment
roups. In accordance with previous results (21), we used
NP response of 32% inhibition of aggregation as a
riterion of severe platelet NO resistance for evaluation of
otential heterogeneity of response to ramipril. We have
reviously demonstrated (29) that inhibition of aggregation
y SNP is dependent on ADP response as a reflection of
hysiological antagonism. Therefore, changes in SNP re-
ponse were analyzed relative to changes in ADP response.
n study 1, analysis of covariance was used to test both the
rimary hypothesis of the study (effects of ramipril on the
SNP/ADP relationship in the entire cohort) and the principal
econdary hypothesis (effects of ramipril in the presence of
latelet NO resistance). Using this analysis, a potentiating
ffect of ramipril on SNP responses would be reflected in an
lteration of the competitive relationship between SNP and
DP response toward sensitization to SNP. Patient char-
cteristics in various groups were compared using nonpaired
tests (all data being normally distributed). Nonpaired
tests were also used to compare changes in other param-
ters (AIx, MDA, ADMA, and cGMP) between treatment
roups. Changes in parameters after 4 weeks of treatment
ere used for examination of the time course of the effects
f ramipril. In study 2, all parameters were analyzed using
aired t tests. All data are expressed as mean  SD unless
therwise stated. All statistical analyses were performed
sing SPSS version 12.0 (SPSS, Inc., Chicago, Illinois).
esults
tudy 1: randomized comparison: SUBJECT CHARACTERISTICS
AND CLINICAL COURSE. One hundred nineteen patients
ere randomized to receive the study medication (Table 1).
lacebo (n  59) and ramipril (n  60) groups were well
atched with regard to all measured parameters, except
tatin therapy, which was more frequent in the placebo
roup. During the 12-week study period, 11 patients of the
otal 119 withdrew (9 from the active treatment group). Of
hese, 3 patients receiving ramipril were withdrawn because
f cough or dizziness and 1 from each group as a result of an
cute coronary syndrome.
PLATELET AGGREGATION AND INHIBITION WITH SNP.
Platelet responsiveness to ADP in blood samples from
subjects was similar between groups at baseline (7.6 2.6
s. 7.4  2.4 , placebo vs. ramipril). There was no
ifferential change in the extent of ADP-induced aggrega-
ion over the 3-month period in both groups (Table 2). At
tudy entry, platelet responsiveness to the antiaggregatory
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Ramipril Reverses Platelet NO Resistance September 4, 2012:887–94effect of SNP was similar between the study groups (47.3 
28.5% vs. 42.4  28.9% inhibition of aggregation, placebo
s. ramipril group, p  0.35). After 3 months of ramipril
therapy, average platelet SNP response increased, but not
significantly (Table 2). On correction of changes in SNP
response for those in ADP response (29), the SNP/ADP
relationship demonstrated an increase in NO responsiveness
in the ramipril treatment group (analysis of covariance, p 
0.001) (Fig. 1).
HETEROGENEITY OF RAMIPRIL EFFECT ON NO RESPON-
SIVENESS. Severe platelet NO resistance (SNP response
32%) was present in 41 patients at baseline (23 of whom
were randomized to ramipril therapy). There was no differ-
ence in the extent of ADP-induced aggregation between the
normal NO responder and impaired NO responder groups.
ADP-induced aggregation was not significantly affected by
3 months of therapy within each subgroup.
NO responsiveness increased markedly after ramipril
therapy in this NO-resistant subgroup of patients, com-
pared with the placebo group (SNP response 36.5 
31.9% vs. 15.9  22.7% inhibition of aggregation, ramipril
vs. placebo, p  0.03) (Fig. 2B). In contrast, platelet NO
responsiveness was unaltered by ramipril in the subgroup
with normal platelet responses at baseline (SNP response
Patient Demographics at Study EntryTable 1 Patient Demographics at Study Entry
Variable
Placebo Group
(n  59)
Ramipril Group
(n  60) p Value
Men 38 (64%) 35 (58%) 0.57
Age (yrs) 66.4 9.7 67.2 10.6 0.65
Height (cm) 166.8 12.0 165.1 18.1 0.43
Weight (kg) 81.5 18.7 81.3 19.5 0.97
BMI (kg/m2) 29.6 9.0 30.2 9.4 0.73
SBP (mm Hg) 144.7 23.2 145.3 24.5 0.88
DBP (mm Hg) 82.6 8.9 80.6 12.7 0.33
HR (beats/min) 68 8.9 66 11.0 0.25
Past MI 28 (48%) 20 (33%) 0.13
CABG 14 (24%) 23 (38%) 0.11
PCI 31 (53%) 22 (37%) 0.09
Diabetes 9 (15%) 15 (25%) 0.25
Smokers 19 (32%) 12 (20%) 0.15
Hypertension 26 (44%) 21 (35%) 0.35
Cholesterol level (mmol/l) 4.2 0.9 4.5 0.9 0.05
Creatinine level (mol/l) 0.092 0.015 0.094 0.019 0.53
Therapy
Aspirin 51 (86%) 54 (90%) 0.58
Statins 57 (97%) 49 (82%) 0.02*
Beta-blockers 9 (15%) 16 (27%) 0.18
Calcium antagonists 41 (69%) 31 (52%) 0.06
Nitrates 22 (37%) 21 (35%) 0.85
Warfarin 5 (8%) 2 (3%) 0.27
Perhexiline 1 (2%) 4 (7%) 0.36
Values are n (%) or mean  SD. *Statistically significant (p  0.05).
BMI  body mass index; CABG  coronary artery bypass grafting; DBP  diastolic blood
ressure; HR  heart rate; MI myocardial infarction; PCI  percutaneous coronary intervention;
BP  systolic blood pressure.4.6  22.2% vs. 5.8  29.1% inhibition of aggregation,
i
Sramipril vs. placebo, p  NS) (Fig. 2A). Thus, effects of
ramipril varied markedly according to the presence or
absence of severe platelet NO resistance at baseline.
TIME COURSE OF RAMIPRIL EFFECT. Interestingly, the week
4 data suggested that some effect of ramipril was already
present at this stage, with a significant sensitization of
platelets (on the basis of the SNP/ADP response rela-
tionship) in the entire cohort (p  0.001).
VASOMOTOR EFFECTS. Three months of ramipril therapy
arginally reduced both systolic blood pressure (11.7 
0.9 mm Hg vs. 5.2  17.5 mm Hg, ramipril vs. placebo,
 0.07) and diastolic blood pressure (6.2  10.3 mm Hg
s. 1.8  10.0 mm Hg, ramipril vs. placebo, p  0.03).
here was no difference in heart rate between the placebo and
amipril groups.
We also examined the effect of ramipril therapy on AIx,
measure of arterial stiffness and wave reflection (24,25). At
tudy entry, there was no difference in AIx between the
lacebo and ramipril groups (23.7  8.9% vs. 24.9  9.3%,
espectively). Three months of ramipril therapy significantly
educed AIx (1.3  8.1 vs. 4.8  10.9, placebo vs.
amipril, p  0.02) (Table 2).
OXIDATIVE STRESS AND ENDOTHELIAL DYSFUNCTION.
Plasma concentrations of MDA and ADMA, used as markers
of oxidative stress and endothelial dysfunction, respectively, are
summarized in Table 2. MDA concentrations were not sig-
nificantly affected by ramipril therapy. ADMA levels were
reduced by ramipril therapy (p  0.05) (Table 2).
Study 2: mechanistic considerations: Study 2 was designed
to determine whether sensitization of platelets to NO by
ramipril was associated with potentiation of NO respon-
siveness of sGC. In view of the apparent heterogeneity of
response to ramipril therapy in study 1, we selected patients
with relatively impaired NO responsiveness. Although the
19 patients recruited for this study were selected on a similar
basis to those in study 1, they tended to be older (mean age
70  9 years), and 11 of the 19 participants had diabetes.
Effect of 3 Months ofRamipril on Measured ParametersTable 2 Effect of 3 Months ofRamipril on Measured Parameters
Change From Baseline
Parameter
Placebo Group
(n  57)
Ramipril Group
(n  51) p Value
HR (beats/min) 1.1 15.5 2.2 8.7 0.63
ADP-induced aggregation () 1.5 2.4 0.9 2.6 0.22
Inhibition of aggregation by
SNP (%)
1.7 28.2 12.3 36.8 0.10
AIx (%) 1.3 8.1 4.8 10.9 0.02
MDA (mol/l) 0.006 0.15 0.042 0.26 0.25
ADMA (nmol/l) 6.9 6.1 15.9 5.9 0.05
SNP-induced intraplatelet
cGMP response (%)
3.1 42.0 3.0 41.7 0.99
Values are mean  SD.
ADMA  asymmetric dimethylarginine; ADP  adenosine diphosphate; AIx  augmentationndex; cGMP  cyclic guanosine monophosphate; HR  heart rate; MDA  malondialdehyde;
NP  sodium nitroprusside.
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September 4, 2012:887–94 Ramipril Reverses Platelet NO ResistancePLATELET AGGREGATION IN RESPONSE TO ADP AND SNP.
There was no significant change in the extent of ADP-
induced platelet aggregation over the 2-week period of
ramipril treatment (data not shown). As intended, baseline
SNP responsiveness was substantially less than for study 1,
with mean baseline value of 24  13% inhibition. With
ramipril treatment, SNP response increased to 37  25%
(p  0.01) (Fig. 3A).
Figure 1 Effect of Ramipril on the Change
in ADP/SNP Response Relationship
This graph illustrates the effect of 3 months of ramipril (blue triangles) or pla-
cebo (red squares) treatment on the change in adenosine diphosphate (ADP)/
sodium nitroprusside (SNP) response relationship in patients at high risk for
cardiovascular events (HOPE [Heart Outcomes Prevention Evaluation]–type
patients). Ramipril (blue dashed line) significantly (p  0.001, analysis of covari-
ance) altered the change in ADP/SNP response relationship compared to placebo
(red solid line).
Figure 2 Effect of Ramipril on Inhibition of Aggregation Accord
These graphs illustrate the effect of 3 months of ramipril (triangles) or placebo (s
aggregation in blood samples from patients with “normal” (normal responders) (A
tant) (B) SNP responsiveness at study entry. Ramipril had no effect on SNP respo
cantly improved SNP responsiveness in patients who were NO resistant at study eINTRAPLATELET CGMP GENERATION IN RESPONSE TO SNP.
Platelet cGMP-generating capacity in response to SNP
significantly increased after 2 weeks of treatment with
ramipril (Fig. 3B), implying improvement in responsiveness
of sGC to NO. Specifically, at baseline, SNP-induced
stimulation of cGMP generation was 249 85% of control,
increasing to 317  114% (p  0.02) after ramipril therapy.
There was a significant correlation (R  0.63, p  0.01)
etween changes in the responsiveness of the platelet-
GMP system and modulation of platelet aggregation by
NP (Fig. 3C).
TSP CONCENTRATIONS. Ramipril treatment induced no sig-
nificant changes in plasma TSP-1 concentrations (baseline
109.5  80.5 ng/ml, post ramipril therapy 93.9  61.2
g/ml, p  0.50).
iscussion
he HOPE study with ramipril (1) and the EUROPA
tudy with perindopril (2) demonstrated that these ACE
nhibitors reduce the risk for cardiovascular events in aging,
igh-risk populations. However, the mechanism(s) under-
ying these beneficial effects have never been delineated and
ave been the subject of considerable speculation (3–8). In
he present study, we provide evidence for an effect of
amipril in HOPE-type patients, which is distinct from
reviously documented beneficial changes to vasomotor
unction (14). Specifically, we demonstrate that ramipril,
hile reducing arterial stiffness and plasma ADMA con-
entrations (consistent with previous findings [8]), potenti-
tes platelet responsiveness to the antiaggregatory effects of
O by selectively ameliorating NO resistance. Further-
ore, we demonstrate that this effect is correlated with the
ensitization of platelet sGC to NO.
Previous studies (13,14) have made it clear that ACE
nhibition does not substantially affect responsiveness to
roaggregatory stimuli in vitro. However, homeostasis of
Baseline SNP Responsiveness
s) treatment on the inhibition of adenosine diphosphate–induced whole-blood
impaired” (sodium nitroprusside [SNP] response 32%, nitric oxide [NO] resis-
ess in the normal responder patient cohort (p  NS). In contrast, ramipril signifi-
 0.002). Data are expressed as mean  SEM.ing to
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Ramipril Reverses Platelet NO Resistance September 4, 2012:887–94platelet function is equally dependent on the integrity of
responsiveness to antiaggregatory autacoids. Several poten-
tial biochemical mechanisms underlie the presence of NO
resistance (see Chirkov and Horowitz [16] for a review).
“Scavenging” of NO by O2
 and inactivation of sGC are
Figure 3 Effect of 2-Week Ramipril Treatment on
SNP Responsiveness and cGMP Generation
These graphs illustrate the changes in the inhibitory effect of sodium nitroprus-
side (SNP) on adenosine diphosphate–induced platelet aggregation (A) and
stimulatory effect of SNP on intraplatelet cyclic guanosine monophosphate
(cGMP) generation (B) after 2 weeks of ramipril therapy. There was a signifi-
cant correlation (R  0.63, p  0.01) between these 2 parameters (C).likely to be the major relevant biochemical disturbances. nNO resistance has been studied extensively at both the
platelet (17) and vascular (30,31) levels. It appears most likely
to occur in the presence of acute coronary syndromes (18),
diabetes mellitus (20), stable angina pectoris (17), and acute
heart failure (15) and has also been documented in aortic
stenosis (32), hypertension (33), and polycystic ovarian syn-
drome (29). Furthermore, we have demonstrated that therapies
that reduce O2
 generation, such as perhexiline (34) and
orrection of hyperglycemia (35), may ameliorate NO resis-
ance. More recently, we have also shown that platelet NO
esistance represents an independent risk factor for car-
iovascular events and mortality (p  0.01 for cardiac
vents) (21). This is analogous to the previously demon-
trated prognostic significance of coronary endothelial
asomotor dysfunction (36).
In study 1, we demonstrated that platelet NO respon-
iveness was very heterogeneous within a HOPE-type
opulation, ranging from normal to severe NO resistance.
lthough overall, ramipril therapy potentiated NO respon-
iveness significantly (with the onset of an effect within 4
eeks), this effect was dependent in magnitude on baseline
NP response, as demonstrated by the data in Figure 2: the
ncrease in responsiveness occurred predominantly within
he subset of patients with severe NO resistance.
We therefore performed study 2 to evaluate this phenom-
non prospectively by choosing a less NO responsive patient
ohort (mean baseline SNP response of 24%). Even after 2
eeks, ramipril potentiated NO responsiveness. Parallel
echanistic investigation revealed that ramipril: 1) in-
reased cGMP generation in response to SNP, suggesting
ensitization of sGC to NO as a fundamental mechanism of
ffect, but 2) did not change plasma levels of TSP-1, a
eported modulator of sGC activity (28).
These results therefore suggest that ramipril ameliorates
O resistance by sensitization of sGC in a TSP-1–
ndependent manner. Given the likelihood that ramipril
xerts similar biochemical effects in platelets and in vascular
mooth muscle, these data in combination suggest that
ndothelial function is improved both by increased genera-
ion of NO and by facilitation of cGMP generation. These
ndings, together with the reduction in plasma ADMA
oncentration (Table 2), also have mechanistic implications
egarding the previously reported beneficial effects of ACE
nhibitors on endothelial function (8–14).
tudy limitations. The study was subject to several limi-
ations. A randomized controlled design for study 2 would
ave been more rigorous but would have imposed consid-
rable recruitment difficulties.
The most important limitation is that NO responsiveness
as examined only in platelets, not in vascular muscle, because
f the difficulty of performing parallel physiological and bio-
hemical studies in human vasculature. However, the observed
hanges in platelet NO-related physiology are of independent
rognostic importance (21). Similarly, it is impossible to
scertain to what extent these changes in platelet responsive-
ess to NOmight have contributed to improved cardiovascular
893JACC Vol. 60, No. 10, 2012 Willoughby et al.
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evaluation of the genetic determinants of effects of perindopril
therapy in EUROPA (37) identified 3 polymorphisms affect-
ing the bradykinin type 1 receptor and angiotensin II type 1
receptor genes that modulated both the risk for cardiovascular
events in EUROPA and the extent of the beneficial effect of
perindopril. There was an inverse relationship between back-
ground event risk and extent of benefit. Because angiotensin II
type 1 receptor stimulation increases superoxide production
(38), while bradykinin type 1 stimulation induces secondary
NO release (39), these observations may reflect additional
factors predictive of NO resistance.
Conclusions
The data from the present study demonstrate that ramipril
sensitizes platelets to NO in a HOPE-type patient population
and that this effect results from sGC-dependent amelioration
of platelet NO resistance. These findings provide an additional
potential basis for the effects of ramipril in reducing risk for
cardiac events.
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